JAMA Cardiology

04/20/2026

At 20-year follow-up after patent foramen ovale closure for paradoxical embolism, recurrent stroke was rare (

04/19/2026

📢 Calling all cardiology clinicians and researchers!

JAMA Cardiology is offering a one-year fellowship for early-career cardiologists and researchers within 10 years of completing their training. Fellows will engage directly in the editorial and peer-review processes, consult with editors, attend weekly and annual meetings, and write commentary for the journal.

📅 Applications are due May 15, 2026.
🔗 Apply here: https://ja.ma/4tfQslT

04/19/2026

Genotype-positive in US adults was linked to higher atherosclerotic cardiovascular disease rates and lower achievement of guideline-recommended LDL-C targets. https://ja.ma/4mFaNyG

04/18/2026

In a US cohort, higher systolic genetic risk was associated with new-onset after pregnancy, but elevated postpartum body mass index and hypertensive disorders of pregnancy were stronger risk factors.

https://ja.ma/4bZtO9T

04/18/2026

Among patients with diabetes and multivessel coronary artery disease, ticagrelor was not noninferior to prasugrel for reducing death, myocardial infarction, stroke, or major bleeding at 1 year after percutaneous coronary intervention. https://ja.ma/4tT6Rwz

04/17/2026

💬 Editorial: The HeartSync-LBBP trial demonstrated greater reductions in heart failure hospitalization and improvements in left ventricular ejection fraction (LVEF) with conduction system pacing compared to biventricular pacing, primarily among selected patients and experienced operators. In contrast, PhysioSync-HF reported inferiority of CSP, with less improvement in LVEF, possibly due to heterogeneous pacing techniques and lower operator experience. These results suggest that CSP may benefit highly selected patients, but its broader adoption requires evidence from appropriately powered trials with clinically meaningful endpoints.

The PhysioSync-HF randomized clinical trial compares conduction system pacing vs biventricular pacing on heart failure–related outcomes in patients with heart failure with reduced ejection fraction and left bundle-branch block.

04/16/2026

Among asymptomatic patients with severe , higher midwall myocardial fibrosis burden was associated with increased death or unplanned hospitalization, but early valve intervention results did not differ by fibrosis burden.

https://ja.ma/4cchYe3

04/16/2026

Among patients with heart failure and LBBB, LBBP demonstrated superior long-term clinical outcomes compared to BiVP, driven primarily by reduced rates of heart failure hospitalization. Both groups showed improvements in and functional status, but the proportion of super responders was greater with LBBP. The high success rate and low complication profile in the LBBP group were attributed to experienced operators and a population predominantly with nonischemic cardiomyopathy.

Cardiac resynchronization therapy (CRT) with biventricular pacing (BiVP) remains a cornerstone treatment for patients with heart failure with reduced ejection fraction and left bundle-branch block (LBBB), supported by decades of randomized evidence demonstrating reductions in mortality and heart...

04/15/2026

Patients with showed increased myocardial fibroblast activation using [68Ga]FAPI-46 PET/MRI, with distinct patterns by cardiomyopathy etiology, highlighting activated fibroblasts as a potential therapeutic target.

https://ja.ma/4826yHg

04/15/2026

📢 Applications Open: 2026–2027 JAMA Cardiology Editorial Fellowship Program

Starting July 2026, this 1-year fellowship will immerse early-career cardiologists or researchers in the editorial and peer-review processes at JAMA Cardiology.

Selected fellows will:
• Be paired with a Deputy or Associate Editor who will provide structured mentorship
• Engage directly with the editorial processes of the journal
• Attend weekly manuscript meetings and an annual Editorial Board meeting
• Contribute editorial/commentary pieces
• Identify emerging areas in their subspecialty fields for research submissions

📍 Eligibility: Doctorate-level clinicians or researchers in cardiology within 10 years of completing their clinical training.
📅 Applications are due May 15, 2026.
🔗 Apply here: https://ja.ma/4syvmxO

04/15/2026

patients at high cardiovascular risk receiving oral demonstrated early and sustained improvements in glycated hemoglobin, body weight, systolic blood pressure, and lipid profiles vs placebo.

https://ja.ma/47liBPJ

04/15/2026

In the PhysioSync-HF randomized clinical trial, conduction system pacing ( ) was inferior to biventricular pacing ( ) for patients with heart failure, left bundle-branch block ( ), and reduced left ventricular ejection fraction ( ) over 12 months. CSP was associated with higher odds of death, heart failure hospitalization, urgent visits, and smaller improvements in LVEF compared to BiVP.

Complication rates and procedural-related deaths were also higher with CSP, and the efficacy of the intervention may have been influenced by heterogeneous operator experience and diverse pacing techniques.

https://ja.ma/4tQ2WAF